JP2019529534A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529534A5 JP2019529534A5 JP2019533300A JP2019533300A JP2019529534A5 JP 2019529534 A5 JP2019529534 A5 JP 2019529534A5 JP 2019533300 A JP2019533300 A JP 2019533300A JP 2019533300 A JP2019533300 A JP 2019533300A JP 2019529534 A5 JP2019529534 A5 JP 2019529534A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- tablet
- trifluoromethyl
- amino
- tablet according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 36
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 34
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 32
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 32
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 32
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 32
- 229940125904 compound 1 Drugs 0.000 claims description 28
- 239000008109 sodium starch glycolate Substances 0.000 claims description 22
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 22
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 230000002062 proliferating effect Effects 0.000 claims description 20
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 108700028369 Alleles Proteins 0.000 claims description 8
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 8
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 229940057948 magnesium stearate Drugs 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 6
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 3
- BRQZOOWELDMGOE-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C[C]=N1 BRQZOOWELDMGOE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000013980 iron oxide Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022150798A JP7487270B2 (ja) | 2016-09-07 | 2022-09-22 | 錠剤組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384643P | 2016-09-07 | 2016-09-07 | |
| US62/384,643 | 2016-09-07 | ||
| US201762535162P | 2017-07-20 | 2017-07-20 | |
| US62/535,162 | 2017-07-20 | ||
| PCT/US2017/050202 WO2018048847A1 (en) | 2016-09-07 | 2017-09-06 | Tablet compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150798A Division JP7487270B2 (ja) | 2016-09-07 | 2022-09-22 | 錠剤組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529534A JP2019529534A (ja) | 2019-10-17 |
| JP2019529534A5 true JP2019529534A5 (https=) | 2020-10-22 |
Family
ID=59895401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533300A Pending JP2019529534A (ja) | 2016-09-07 | 2017-09-06 | 錠剤組成物 |
| JP2022150798A Active JP7487270B2 (ja) | 2016-09-07 | 2022-09-22 | 錠剤組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150798A Active JP7487270B2 (ja) | 2016-09-07 | 2022-09-22 | 錠剤組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11389454B2 (https=) |
| EP (1) | EP3509570A1 (https=) |
| JP (2) | JP2019529534A (https=) |
| KR (1) | KR102498693B1 (https=) |
| CN (2) | CN109715143A (https=) |
| AU (1) | AU2017324844B2 (https=) |
| BR (1) | BR112019004356A2 (https=) |
| CA (1) | CA3036053A1 (https=) |
| CL (1) | CL2019000573A1 (https=) |
| CO (1) | CO2019002092A2 (https=) |
| EC (1) | ECSP19015828A (https=) |
| IL (1) | IL265126B2 (https=) |
| MX (1) | MX392941B (https=) |
| SG (1) | SG11201901873PA (https=) |
| WO (1) | WO2018048847A1 (https=) |
| ZA (1) | ZA201901321B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| MX392941B (es) * | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092906A1 (en) * | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092915A1 (en) * | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020239759A1 (en) * | 2019-05-27 | 2020-12-03 | Sandoz Ag | Amorphous enasidenib in a stabilized form |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| AR126195A1 (es) * | 2021-06-23 | 2023-09-27 | Blueprint Medicines Corp | Composiciones farmacéuticas de un inhibidor del receptor del factor de crecimiento epidérmico |
| WO2024008138A1 (zh) * | 2022-07-07 | 2024-01-11 | 正大天晴药业集团股份有限公司 | 1,3,5-三嗪衍生物的药物组合 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225964B1 (en) * | 1994-07-12 | 2008-01-28 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
| TW430561B (en) * | 1995-12-20 | 2001-04-21 | Gea Farmaceutisk Fabrik As | Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet |
| AR016827A1 (es) * | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| IL159853A0 (en) * | 2001-07-17 | 2004-06-20 | Teva Pharma | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| US20070010466A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| AU2010316683B2 (en) * | 2009-11-09 | 2015-10-08 | Wyeth Llc | Tablet formulations of neratinib maleate |
| WO2012027247A2 (en) * | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| NZ627096A (en) | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| MY185687A (en) | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| KR102316886B1 (ko) * | 2013-08-02 | 2021-10-19 | 아지오스 파마슈티컬스 아이엔씨. | 치료학적 활성 화합물 및 이의 사용방법 |
| TWI666208B (zh) * | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| CA3254279A1 (en) * | 2015-06-03 | 2025-03-18 | Triastek, Inc. | PHARMACEUTICAL FORMS AND RELATED USES |
| CA2993615A1 (en) | 2015-08-05 | 2017-02-09 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| CN108366980A (zh) | 2015-10-15 | 2018-08-03 | 安吉奥斯医药品有限公司 | 用于治疗恶性肿瘤的组合疗法 |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| ES2912909T3 (es) | 2016-02-26 | 2022-05-30 | Celgene Corp | Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria |
| MX392941B (es) * | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
-
2017
- 2017-09-06 MX MX2019002697A patent/MX392941B/es unknown
- 2017-09-06 CA CA3036053A patent/CA3036053A1/en not_active Abandoned
- 2017-09-06 KR KR1020197006492A patent/KR102498693B1/ko active Active
- 2017-09-06 US US15/697,199 patent/US11389454B2/en active Active
- 2017-09-06 JP JP2019533300A patent/JP2019529534A/ja active Pending
- 2017-09-06 BR BR112019004356-0A patent/BR112019004356A2/pt not_active Application Discontinuation
- 2017-09-06 AU AU2017324844A patent/AU2017324844B2/en active Active
- 2017-09-06 WO PCT/US2017/050202 patent/WO2018048847A1/en not_active Ceased
- 2017-09-06 EP EP17768583.1A patent/EP3509570A1/en active Pending
- 2017-09-06 SG SG11201901873PA patent/SG11201901873PA/en unknown
- 2017-09-06 CN CN201780054265.1A patent/CN109715143A/zh active Pending
- 2017-09-06 CN CN202510669668.3A patent/CN120501712A/zh active Pending
- 2017-09-06 IL IL265126A patent/IL265126B2/en unknown
-
2019
- 2019-03-01 ZA ZA2019/01321A patent/ZA201901321B/en unknown
- 2019-03-05 CO CONC2019/0002092A patent/CO2019002092A2/es unknown
- 2019-03-06 EC ECSENADI201915828A patent/ECSP19015828A/es unknown
- 2019-03-06 CL CL2019000573A patent/CL2019000573A1/es unknown
-
2022
- 2022-06-21 US US17/845,807 patent/US20220323447A1/en not_active Abandoned
- 2022-09-22 JP JP2022150798A patent/JP7487270B2/ja active Active
-
2024
- 2024-06-17 US US18/745,080 patent/US20240335450A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529534A5 (https=) | ||
| US20240360118A1 (en) | Bicyclic Compounds and their Uses | |
| JP7487270B2 (ja) | 錠剤組成物 | |
| JP7456721B2 (ja) | ５－メチル－１－フェニル－２－（１ｈ）－ピリドンの顆粒製剤及びその製造方法 | |
| JP2017525757A5 (https=) | ||
| JP2016525076A5 (https=) | ||
| JP2019502669A5 (https=) | ||
| JP2019506387A5 (https=) | ||
| JP2017527602A5 (https=) | ||
| JP2015529194A5 (https=) | ||
| JP7665702B2 (ja) | アキシチニブを含有する医薬組成物 | |
| WO2020070144A1 (en) | Crystalline forms and processes of lenvatinib besylate | |
| KR102904026B1 (ko) | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 | |
| CN104546776A (zh) | 瑞戈非尼片剂药物组合物和制法 | |
| EP2425830A1 (en) | Synergistic drug combination for the treatment of cancer | |
| JPWO2022132652A5 (https=) | ||
| JP2020531485A5 (https=) | ||
| US11730753B2 (en) | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride | |
| JP6937308B2 (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| JP2019147798A (ja) | ダサチニブ無水物の結晶形態が安定に維持された固形製剤の製造方法 | |
| JP2018184381A (ja) | エゼチミブ含有錠剤およびその製法 | |
| JP2021191801A (ja) | ブロナンセリン含有錠剤 | |
| US20160015646A1 (en) | Oral delivery system for sorafenib tosylate | |
| JP6199922B2 (ja) | 化学的な安定性が向上したイルベサルタン含有錠剤 | |
| SA05260133B1 (ar) | تركيبات صيدلانية تشتمل على zd6474 |